Literature DB >> 18806751

Expression of MDR1, LRP, BCRP and Bcl-2 genes at diagnosis of childhood all: comparison with MRD status after induction therapy.

U U Fedasenka1, T V Shman, V P Savitski, M V Belevcev.   

Abstract

AIM: to investigate properties of leukemic cells by sorting out children diagnosed with ALL with different response to chemotherapy based on MRD level.
METHODS: We used a minimal residual disease (MRD) data on day 36 obtained with 3-colour flow cytometry as a reference. In view of MRD results, we used real-time PCR to assess expression levels of multidrug resistance associated genes MDR1, LRP and BCRP, antiapoptotic gene Bcl-2 in initial samples from children diagnosed with ALL. P-gp expression and function in initial samples were analyzed by flow cytometry.
RESULTS: Briefly, medians of relative expression levels of MDR1 gene were roughly comparable and in MRD(+) group came to 22.8 (0.02-26.6; n = 9) vs 24.8 (3.9-41.4; n = 10) in MRD(-) group. Bcl-2 gene showed tendency to higher expression levels in MRD(+) group with median at 5992.9 (521.0-10362.0; n = 9) compared to 3183.6 (1947.9-6581.0; n = 10) in MRD(-) group. LRP gene relative expression levels were similar in both groups and came to 1934.9 (1500.7-3490.4; n = 9) and 1408.5 (665.5-2917.1; n = 10) in MRD + and MRD(-) groups, respectively. The median of BCRP expression levels in MRD + group was considerably lower than that in MRD - group, namely 76000.0 (48196.2-169230.8; n = 9) and 227967.2 (16683.7-422222.2; n = 10), respectively, but statistical analysis showed no significant difference for this parameter.
CONCLUSION: We investigated expression of multidrug resistance genes MDR1, LRP and BCRP and antiapoptotic gene Bcl-2 in leukemic cells at diagnosis, and MRD level at the end of induction therapy, and could not find obvious relations between these parameters.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806751

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  4 in total

Review 1.  Importance of detecting multidrug resistance proteins in acute leukemia prognosis and therapy.

Authors:  Ana Carolina Rabello de Moraes; Caroline Klein Maranho; Gabriela Schneider Rauber; Maria Cláudia Santos-Silva
Journal:  J Clin Lab Anal       Date:  2013-01-04       Impact factor: 2.352

Review 2.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

Review 3.  The challenge of exploiting ABCG2 in the clinic.

Authors:  Robert W Robey; Caterina Ierano; Zhirong Zhan; Susan E Bates
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

4.  Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia.

Authors:  Y Lu; S K Y Kham; H Ariffin; A M I Oei; H P Lin; A M Tan; T C Quah; A E J Yeoh
Journal:  Br J Cancer       Date:  2014-01-16       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.